Apart the already cited sorafenib, regorafenib, and erlotinib, the drugs brivanib, gefitinib, lapatinib, imatinib, and apatinib were also introduced in clinical studies as anti-EGFR drugs, thus confirming the important role played by the pathway EGF-EGFR in the development of HCC. The gene discussed is EGF; the disease is hepatocellular carcinoma.